Heron Therapeutics' stock price surge may be positive, but the company's core business performance will decide the sustainability of this turnaround. Lack of profitability and minimal revenue growth could discourage potential investors.
Heron Therapeutics' projected breakeven and profitability rely on optimistic growth estimates. The company's negative equity, possibly due to accounting methods, raises concerns.
$Heron Therapeutics(HRTX.US)$Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Heron Therapeutics股票討論區
$Heron Therapeutics(HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$賽諾菲安萬特(SNY.US)$ & $再生元製藥公司(REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
暫無評論